Article
Discovery of a novel third-generation EGFR inhibitor and identification of a potential combination strategy to overcome resistance.
Molecular cancer - 13 May 2020
Zhang Tao, Qu Rong, Chan Shingpan, Lai Mengzhen, Tong Linjiang, Feng Fang, Chen Hongyu, Song Tingting, Song Peiran, Bai Gang, Liu Yingqiang, Wang Yanan, Li Yan, Su Yi, Shen Yanyan, Sun Yiming, Chen Yi, Geng Meiyu, Ding Ke, Ding Jian, Xie Hua
Abstract excerpt
BACKGROUND: Non-small cell lung cancer (NSCLC) patients with activating EGFR mutations initially respond to first-generation EGFR inhibitors; however, the efficacy of these drugs is limited by acquired resistance driven by the EGFR T790M mutation. The discovery of third-generation EGFR inhibitors overcoming EGFR T790M and their new resistance mechanisms have attracted much attention. METHODS: We examined the...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.